Equity Overview
Price & Market Data
Price: $0.02
Daily Change: $0.00 / 0.00%
Daily Range: $0.014 - $0.021
Market Cap: $5,301,032
Daily Volume: 315,024
Performance Metrics
1 Week: 1,900%
1 Month: 81.82%
3 Months: -35.69%
6 Months: -90.24%
1 Year: -93.08%
YTD: -25.65%
Company Details
Employees: 506
Sector: Health technology
Industry: Biotechnology
Country: United Kingdom
Details
Adaptimmune Therapeutics plc, a commercial-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops TECELRA (famitresgene autoleucel or afami-cel), a genetically modified autologous T-cell immunotherapy for the treatment of adults with unresectable or metastatic synovial sarcoma; Lete-cel for the treatment of synovial sarcoma and myxoid liposarcoma; and ADP-5701, which is in Phase 1 clinical trial for the treatment of head and neck cancer. The company also focuses on the development of T-cell therapies directed to PRAME (ADP-600) and CD70 (ADP-520). It has a strategic collaboration with Galápagos for a clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel produced on Galápagos' decentralized manufacturing platform (ADP-5701) in patients with head and neck cancer; a collaboration and license agreement with Noile-Immune Biotech, Inc. and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.